Abstract：Objective：To observe the clinical effect of modified Zhipu Liujunzi tang combined with transcatheter hepatic arterial chemoembolization(TACE) for primary liver cancer. Methods：A total of 68 cases of patients with primary liver cancer undergoing TACE were selected and divided into the observation group and the control group according to the random number table method，34 cases in each group. The control group was treated with TACE，and the observation group was additionally treated with modified Zhipu Liujunzi tang based on the treatment of the control group. The changes in the content levels of intercellular adhesion molecule-1(ICAM-1)，vascular endothelial growth factor(VEGF) and transforming growth factor-β1(TGF-β1) in serum before and after treatment as well as the clinical effect in the two groups were compared； Chinese medicine syndrome scores were counted. Results：The total effective rate was 85.30% in the observation group and 61.77% in the control group，the difference being significant(P＜0.05). Before treatment，there was no significant difference being found in the comparison of the levels of ICAM-1，VEGF and TGF-β1 in serum between the two groups(P＞0.05). After treatment，the levels of ICAM-1，VEGF and TGF-β1 in serum in the two groups were lower than those before treatment(P＜0.05)，and the levels in the observation group were lower than those in the control group(P＜0.05). Before treatment， there was no significant difference being found in the comparison of Chinese medicine syndrome scores between the two groups(P＞0.05). Two and four weeks after surgery，Chinese medicine syndrome scores in the two groups were decreased gradually，and the score at four weeks after surgery in the observation group was lower than that in the control group， differences being significant(P＜0.05). Conclusion：Modified Zhipu Liujunzi tang can reduce the content levels of ICAM-1，VEGF and TGF-β1 in serum of patients with primary liver cancer after TACE and improve the clinical effect.